Allergan Fights Generic Headwinds, Activist Investors
Executive Summary
Chairman/CEO Saunders says the board has determined that keeping him in the dual role is the right move going forward. He added that the company, which had a strong second quarter, won’t be rushed in its efforts to divest its women’s health and infectious disease units.
You may also be interested in...
Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies
Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.
Allergan's Botox Holds Its Own In Migraine, Despite CGRP Competition
In the third quarter, generics of dry eye drug Restasis did not emerge as expected and Botox enjoyed double digit sales for therapeutic indications in the US, despite the entry of new competition in migraine treatment.
Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection
US FDA issued a complete response letter for ulipristal acetate for the treatment of bleeding in women with uterine fibroids. The action wasn't unanticipated, but a disappointment nonetheless while Allergan tries to sell its women's health unit.